A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19

New England Journal of Medicine

Volumn 382, Issue 19, 2020, Pages 1787-1799

  Cao, B ^a,c   Wang, Y ^a,c   Wen, D ^j   Liu, W ^j   Wang, Jingli ^j   Fan, G ^a,b   Ruan, L ^j   Song, B ^j   Cai, Y ^j   Wei, M ^j   Li, X ^d   Xia, J ^j   Chen, N ^j   Xiang, J ⁿ   Yu, T ^j   Bai, T ^j   Xie, X ^j   Zhang, L ^j   Li, C ^j   Yuan, Y ^j   Chen, H ^j   Li, Huadong ^j   Huang, H ^j   Tu, S ^j   Gong, F ^j   Liu, Y ^j   Wei, Y ^j   Dong, C ^e   Zhou, F ^a,c   Gu, X ^a,b   Xu, J ^f   Liu, Z ^a,c   Zhang, Y ^a,c   Li, Hui ^a,c   Shang, L ^a   Wang, K ^j   Li, K ^j   Zhou, X ^j   Dong, X ^j   Qu, Z ^a,j   Lu, S ^j   Hu, X ^j   Ruan, S ^j   Luo, S ^g,j   Wu, J ^j   Peng, L ^j   Cheng, F ^j   Pan, L ^j   Zou, J ^j   Jia, C ^j   Wang, Juan ^j   Liu, X ^j   Wang, S ^j   Wu, X ^j   Ge, Q ^j   He, J ^j   Zhan, H ^j   Qiu, F ^j   Guo, L ^h,i   Huang, C ^j   Jaki, T ^k   Hayden, F G ^m   Horby, P W ^l   Zhang, D ^j   Wang, C ^a,c,i   more..

^a National Clinical Research Center for Respiratory Diseases   (China)

^b Institute of Clinical Medical Sciences   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e PEKING UNIVERSITY   (China)

^f Tsinghua University   (China)

^g University of Chinese Medicine   (China)

^h INSTITUTE OF PATHOGEN BIOLOGY   (China)

ⁱ PEKING UNION MEDICAL COLLEGE   (China)

^j Jinyintan Hospital   (China)

^k LANCASTER UNIVERSITY   (United Kingdom)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m UNIVERSITY OF VIRGINIA   (United States)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; LOPINAVIR PLUS RITONAVIR; VIRUS RNA; ANTIVIRUS AGENT; CYTOCHROME P450 3A INHIBITOR; LOPINAVIR; RITONAVIR;

ABDOMINAL DISCOMFORT; ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMBIENT AIR; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD OXYGEN TENSION; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUSHING; GASTRITIS; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; LABORATORY TEST; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OXYGEN SATURATION; PNEUMOTHORAX; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; SECONDARY INFECTION; SEPSIS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SHOCK; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL; UNCONSCIOUSNESS; VOMITING; BETACORONAVIRUS; COMBINATION DRUG THERAPY; CORONAVIRUS INFECTION; GENETICS; HOSPITAL MORTALITY; INTENTION TO TREAT ANALYSIS; ISOLATION AND PURIFICATION; LABORATORY TECHNIQUE; MIDDLE AGED; MORTALITY; PANDEMIC; PATIENT ACUITY; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME TO TREATMENT; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD; VIRUS PNEUMONIA;

ADULT; AGED; ANTIVIRAL AGENTS; BETACORONAVIRUS; CLINICAL LABORATORY TECHNIQUES; CORONAVIRUS INFECTIONS; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENTION TO TREAT ANALYSIS; LOPINAVIR; MALE; MIDDLE AGED; PANDEMICS; PATIENT ACUITY; PNEUMONIA, VIRAL; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RITONAVIR; TIME-TO-TREATMENT; TREATMENT FAILURE; VIRAL LOAD;

EID: 85082474264     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa2001282     Document Type: Article

References (26)

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
3. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020 February 7 (Epub ahead of print).
4. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020 February 7 (Epub ahead of print).
5. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-6.
6. Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004;31:69-75.
7. Wu C-Y, Jan J-T, Ma S-H, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A 2004;101:10012-7.
8. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014;58:4875-84.
9. Chan JF-W, Yao Y, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015;212:1904-13.
10. Kim UJ, Won E-J, Kee S-J, Jung S-I, Jang H-C. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther 2016;21:455-9.
11. Spanakis N, Tsiodras S, Haagmans BL, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 2014;44: 528-32.
12. Min C-K, Cheon S, Ha N-Y, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep 2016;6: 25359.
13. Chan JFW, Chan K-H, Kao RYT, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013;67:606-16.
14. Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014;95:571-7.
15. Arabi YM, Alothman A, Balkhy HH, et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 2018;19:81.
16. International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) home page (https://isaric.tghn.org/).
17. Wang Y, Fan G, Salam A, et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J Infect Dis 2019 December 11 (Epub ahead of print).
18. Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization (http://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/ en/).
19. National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. London: Royal College of Physicians, 2017 (https://www.rcplondon.ac.uk/projects/outputs/national -early-warning-score-news-2).
20. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003;9:399-406.
21. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014;2:395-404.
22. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012;55: 1198-204.
23. Katzen J, Kohn R, Houk JL, Ison MG. Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes. Clin Infect Dis 2019;69:52-8.
24. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 March 11 (Epub ahead of print).
25. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;382:1177-9.
26. Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Com-mun 2004;318:719-25.